Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/ACE inhibitors and ARBs: similar cardiovascular protection
Comparative · ACEARB-COMP-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Two large randomised trials that pitted an ARB directly against an ACE inhibitor found no meaningful difference in combined heart outcomes: one in people with vascular disease or high-risk diabetes [1], the other in people after a heart attack [2]. Several very large analyses of routine patient records designed to reproduce the first of those trials reached almost the same answer across broad everyday populations [8][11][12]. Smaller observational studies pointed in both directions without a consistent winner [3][7][10]. The main exceptions were a signal that the ARB was linked to more cardiovascular deaths in Black patients [8] and a repeated edge for the ACE inhibitor after a heart attack [4][5][13]. The panel treated comparability as the general rule while flagging these specific exceptions, which is why the 'most populations' wording was judged to fit the evidence rather than overstate it.
The corpus contains two head-to-head randomised trials showing equivalence on composite cardiovascular endpoints: ONTARGET reported a relative risk of 1.01 (95% CI 0.94 to 1.09) for telmisartan versus ramipril [1], and VALIANT reported a hazard ratio of 1.00 (97.5% CI 0.90 to 1.11) with the valsartan-captopril comparison meeting noninferiority post-MI [2]. Large routine-care emulations of ONTARGET reproduced near-unity primary-composite hazard ratios of 0.96 (95% CI 0.95 to 0.98) [8] and 0.97 (95% CI 0.93 to 1.01) [11], and a pooled emulation of ACCORD-BP and SPRINT found similar event rates [12]. Observational cohorts diverge without a consistent direction: REACH favoured ARB (HR 0.90, 95% CI 0.86 to 0.95) [3], a Taiwan AMI cohort found no MACE difference (aHR 0.98, 95% CI 0.90 to 1.07) [10], and a T2DM emulation trended toward ACEi (3-point MACE HR 0.86, 95% CI 0.68 to 1.10) [7]. Narrow exceptions appear in Black patients for cardiovascular death [8] and in post-MI populations favouring ACEi [4][5][13]. The contested point: The evidence divides on whether comparability is uniform: [8] found ARB associated with more cardiovascular death in Black individuals (HR 1.20, 95% CI 1.02 to 1.40, NNH 93) while favouring ARB in White individuals, and post-MI cohorts repeatedly favour ACEi ([4] MACE HR 0.843; [5] cardiac death HR 1.60; [13] MACCE HR 1.34) even though the randomised post-MI trial [2] was null. The split is between the null randomised backbone and directionally inconsistent, confounded observational subgroups.
All 28 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Comparability is not uniform: [8] found ARB associated with MORE cardiovascular death in Black individuals (HR 1.20, 1.02-1.40, NNH 93), a genuine population-specific exception that strains 'most populations' uniformity.
Post-MI cohorts consistently favour ACEi ([4] MACE HR 0.84; [5] cardiac death HR 1.60 against ARB; [13] MACCE HR 1.34 against ARB), a recurring non-comparability signal in one population — though the post-MI RCT [2] was null.
Where it remains uncertain. ARB was associated with more cardiovascular death in Black patients (HR 1.20, 95% CI 1.02 to 1.40) [8], and post-MI cohorts repeatedly favour ACEi [4][5][13], so comparability is not uniform across every population.
Aleatory
Cardiovascular-death differences surface only in specific subgroups such as Black patients [8], where event counts and random variation make the direction harder to pin down than the primary composite.
The load-bearing papers from a corpus of 28, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Landmark head-to-head RCT: ARB equivalent to ACEi on composite CV outcome in high-risk vascular/diabetic patients.
“the primary outcome had occurred in 1412 patients in the ramipril group (16.5%), as compared with 1423 patients in the telmisartan group (16.7%; relative risk, 1.01; 95% confidence interval [CI], 0.94 to 1.09)”
Panel auditInternal validity: high · scope of inference: Patients with established vascular disease or high-risk diabetes without heart failure.Key limitations: excludes heart failure patients · telmisartan ran slightly lower BP
Head-to-head RCT establishing noninferiority for death and CV events post-MI.
“Valsartan is as effective as captopril in patients who are at high risk for cardiovascular events after myocardial infarction.”
Panel auditInternal validity: high · scope of inference: Patients 0.5–10 days after acute MI complicated by LV systolic dysfunction, heart failure, or both.Key limitations: post-MI LV-dysfunction population only · noninferiority not superiority design
Older T2DM emulation: non-significant trend favouring ACEi, CI crosses unity.
“The adjusted hazard ratio for ACEIs vs. ARBs was 0.86 (95% confidence interval [CI], 0.68-1.10) for 3-point MACE”
Panel auditInternal validity: medium · scope of inference: Patients aged 65+ with type 2 diabetes newly starting ACEI or ARB.Key limitations: observational · secondary 4-point MACE marginally favoured ACEI · small ACEI arm
Registry cohort showing a modest ARB advantage confined to established CVD (directional heterogeneity vs RCTs).
“ARB use appears to be associated with 10% lower rates of CV events compared with ACEIs, especially in patients with established CV disease”
Panel auditInternal validity: medium · scope of inference: Patients at high cardiovascular risk in real-world practice, benefit concentrated in those with established atherosclerosis.Key limitations: observational, confounding by indication · difference only in secondary-prevention subgroup
4 of 28 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Comparability for composite CV events is carried by robust randomised head-to-head data and large emulations, held just below Established by real subgroup heterogeneity and the observational softness of the cohort evidence.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Randomised ACEi-versus-ARB comparison in Black patients. The only population where a class difference in cardiovascular death appears [8] is observational; the claim's uniformity hinges on whether this exception is real. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A head-to-head randomised trial or a prospectively pre-registered target-trial emulation powered for cardiovascular death in Black patients.
Open question: Is the increased cardiovascular-death risk with ARB versus ACEi in Black patients a real class difference or a product of residual confounding? Why it is still open: The signal rests on a single observational emulation [8] (HR 1.20, 95% CI 1.02 to 1.40) with no randomised confirmation in the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19